Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report
Mashal Salehi1,2, Robertha Miller3,4, Myint Khaing3,4
1Department of Medicine, NYC Health and Hospitals/Harlem, Columbia University, New York, USA. Salehi.MashaL@yahoo.com.
Background:
Methotrexate has been implicated in a variety of lung complications, one of which is hypersensitivity pneumonitis. Hypersensitivity pneumonitis most often occurs within the first year of starting low-dose orally administered methotrexate. We present a case of methotrexate-induced hypersensitivity pneumonitis after 30 years of methotrexate use, which is the first case to be reported so far.
Case Presentation:
A 77-year-old African American woman with a history of rheumatoid arthritis presented with progressively worsening shortness of breath and nonproductive cough. She was on a daily dose of 2.5 mg of methotrexate that had been orally administered for the last 30 years. A physical examination was significant for fever of 38.2 °C (100.8 °F), tachycardia, bilateral basal crackles, and oxygen saturation of 88% on room air. A laboratory work up was significant for normal white blood cell count, increased eosinophil count of 18.3%, and erythrocyte sedimentation rate of 111 mm/hour. Sputum cultures were negative for any bacterial pathogens including acid-fast bacilli. Influenza and respiratory syncytial viral infection were ruled out. A (1-3)-B-D-glucan assay (Fungitell®) was within normal limits. Pulmonary embolism was ruled out and echocardiography was normal. A chest X-ray showed hazy opacity with prominent reticulation within the upper lung fields bilaterally, right greater than the left with no pleural effusion. Lung computed tomography revealed nonspecific bilateral upper lung opacification. A pulmonary function test was significant for no obstruction, normal maximum voluntary ventilation, and no restriction, with mildly decreased diffusion. Methotrexate was stopped, and our patient was started on prednisone 60 mg orally administered daily with dramatic clinical and radiologic improvement.
Conclusions:
Methotrexate-induced hypersensitivity pneumonitis usually occurs in the initial few weeks to months of starting treatment with methotrexate; however, it can occur late during therapy too, and prompt diagnosis is crucial as it is a reversible condition when diagnosed early.
Insights
This case report details a rare instance of hypersensitivity pneumonitis caused by methotrexate after 30 years of use. Early diagnosis and treatment with steroids led to significant recovery, highlighting that drug-induced lung disease can manifest late.
Area of Science:
- Pulmonology
- Rheumatology
- Clinical Pharmacology
Background:
- Methotrexate (MTX) is a widely used disease-modifying antirheumatic drug (DMARD).
- MTX is associated with various pulmonary complications, including hypersensitivity pneumonitis (HP).
- MTX-induced HP typically occurs within the first year of treatment.
Observation:
- A 77-year-old woman with rheumatoid arthritis developed progressive dyspnea and cough after 30 years of daily low-dose oral MTX.
- Clinical presentation included fever, tachycardia, hypoxia, and characteristic lung imaging findings.
- Laboratory results showed eosinophilia and elevated ESR, with negative infectious workup.
Findings:
- The patient was diagnosed with methotrexate-induced hypersensitivity pneumonitis.
- Discontinuation of MTX and initiation of high-dose corticosteroids resulted in rapid clinical and radiological improvement.
- This represents the first reported case of MTX-induced HP occurring after 30 years of continuous therapy.
Implications:
- Methotrexate-induced hypersensitivity pneumonitis can occur even after prolonged therapy.
- Prompt recognition and management are critical for reversing MTX-induced lung disease.
- Clinicians should maintain a high index of suspicion for MTX-HP in patients with respiratory symptoms, regardless of treatment duration.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Drug Toxicity: Allergic Reactions
Pneumothorax-II
Clinical Manifestations:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

